KR20220128363A - 항-인간 hvem(tnfrsf14) 항체 및 그의 용도 - Google Patents

항-인간 hvem(tnfrsf14) 항체 및 그의 용도 Download PDF

Info

Publication number
KR20220128363A
KR20220128363A KR1020227025697A KR20227025697A KR20220128363A KR 20220128363 A KR20220128363 A KR 20220128363A KR 1020227025697 A KR1020227025697 A KR 1020227025697A KR 20227025697 A KR20227025697 A KR 20227025697A KR 20220128363 A KR20220128363 A KR 20220128363A
Authority
KR
South Korea
Prior art keywords
hvem
human
ser
antibody
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227025697A
Other languages
English (en)
Korean (ko)
Inventor
루이스 분
페트루스 요하네스 시몬스
마르쉘 떼오도러스 덴 하르토그
Original Assignee
제이제이피 바이오로직스 에스피. 제트 오.오.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이제이피 바이오로직스 에스피. 제트 오.오. filed Critical 제이제이피 바이오로직스 에스피. 제트 오.오.
Publication of KR20220128363A publication Critical patent/KR20220128363A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227025697A 2019-12-24 2020-12-24 항-인간 hvem(tnfrsf14) 항체 및 그의 용도 Pending KR20220128363A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19219684 2019-12-24
EP19219684.8 2019-12-24
PCT/NL2020/050817 WO2021133170A1 (en) 2019-12-24 2020-12-24 Anti-human hvem (tnfrsf14) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20220128363A true KR20220128363A (ko) 2022-09-20

Family

ID=69061152

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025697A Pending KR20220128363A (ko) 2019-12-24 2020-12-24 항-인간 hvem(tnfrsf14) 항체 및 그의 용도

Country Status (10)

Country Link
US (1) US12503516B2 (https=)
EP (1) EP4081541A1 (https=)
JP (1) JP7681025B2 (https=)
KR (1) KR20220128363A (https=)
CN (1) CN115087672A (https=)
AU (1) AU2020414265A1 (https=)
BR (1) BR112022012725A2 (https=)
CA (1) CA3162656A1 (https=)
MX (1) MX2022007855A (https=)
WO (1) WO2021133170A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4265639A2 (en) * 2020-12-15 2023-10-25 Medytox Inc. Anti-hvem antibody, and composition and method associated with same
US20240317871A1 (en) * 2020-12-30 2024-09-26 Immunomic Therapeutics, Inc. Anti-HVEM Antibodies
CN116715769B (zh) * 2022-05-26 2024-06-25 四川大学 抗hvem抗体、制备方法及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US8188232B1 (en) * 2004-11-15 2012-05-29 Washington University In St. Louis Compositions and methods for modulating lymphocyte activity
WO2010006071A1 (en) * 2008-07-08 2010-01-14 La Jolla Institute For Allergy And Immunology Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006090385A2 (en) * 2005-02-22 2006-08-31 Ramot At Tel-Aviv University Ltd. Protease inhibitors and method of screening thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2008146101A1 (en) 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Ligands of hvem for treating hematologic malignancies and autoimmune diseases
EP3002296B1 (en) * 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla antibodies and uses thereof
TWI427085B (zh) * 2011-11-02 2014-02-21 國立成功大學 活化纖維蛋白溶酶原之抗體、其用途以及含有其之製劑
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
EP2985294A1 (en) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
CA2981304C (en) * 2015-04-02 2024-01-02 Memorial Sloan Kettering Cancer Center Tnfrsf14/hvem proteins and methods of use thereof
US10562952B2 (en) * 2015-09-10 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 chimeric antigen receptors
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
US12036242B2 (en) * 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
WO2020095249A1 (en) * 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
BR112021021645A2 (pt) * 2019-04-29 2021-12-21 4C Biomed Ltd Anticorpos anti-hvem e uso dos mesmos.
JP7716393B2 (ja) * 2019-10-04 2025-07-31 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗ｋｉｒ３ｄｌ３抗体およびそれらの使用

Also Published As

Publication number Publication date
US20230052646A1 (en) 2023-02-16
MX2022007855A (es) 2022-09-23
WO2021133170A1 (en) 2021-07-01
US12503516B2 (en) 2025-12-23
AU2020414265A1 (en) 2022-07-21
BR112022012725A2 (pt) 2022-11-16
JP2023522520A (ja) 2023-05-31
EP4081541A1 (en) 2022-11-02
JP7681025B2 (ja) 2025-05-21
CN115087672A (zh) 2022-09-20
CA3162656A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
US20240124583A1 (en) Proteins Comprising Kallikrein Related Paptidase 2 Antigen Binding Domains And Their Uses
JP2023105024A (ja) 抗体およびその使用方法
RU2753493C2 (ru) Анти-ох40 антитела и их применение
JP2021508676A (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
TW202124415A (zh) 抗ｔｎｆｒ２抗體及使用方法
US20190225690A1 (en) Novel anti-ctla4 antibodies
AU2019248547B2 (en) Anti-TREM-1 antibodies and uses thereof
JP2019519223A (ja) 免疫調節タンパク質及び腫瘍抗原に結合する二重特異性結合タンパク質
AU2017414149A1 (en) Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
KR20180040671A (ko) Bcma와 cd3에 결합하는 이중특이성 항원 결합 분자인 항-bcma 항체, 및 이들의 용도
JP7681025B2 (ja) 抗ヒトｈｖｅｍ（ｔｎｆｒｓｆ１４）抗体およびそれらの使用
KR20240128709A (ko) 신규한 항-tslp 항체
TW202235104A (zh) 雙功能分子
US12435151B2 (en) Anti-TNFR2 antibodies and uses thereof
KR20160010391A (ko) Cd20 및 cd95에 결합하는 재조합 이중특이성 항체
JP2023522520A5 (https=)
KR20230113752A (ko) Cd39 및 tgf베타를 표적화하는 신규 접합체 분자
CA3199839A1 (en) Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
KR20190026766A (ko) 항-il-22r 항체
AU2022301381A1 (en) Anti-cd3 antibody and use thereof
JP2026508244A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体
CA3097253A1 (en) Antibodies targeting glycoprotein vi
EA049801B1 (ru) Антитела против hvem человека (tnfrsf14) и их применение
RU2831786C2 (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К Vβ17/CD123
AU2024322975A1 (en) Anti-ox40l antibody and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902